This page lists medtech venture capital firms in Sweden, from specialist life science investors such as HealthCap and Eir Ventures to generalist and early-stage funds. Seed and Series A rounds dominate, the most common ticket is checks of $10 million to $50 million, and a smaller group of funds writes checks under $1 million for first rounds.
Medtech venture capital firms in Sweden: where the money goes
Sweden has a long record in medical technology and life sciences, built on strong university research, a large public hospital system, and established pharma and device companies. That mix produces a steady flow of spinouts in devices, diagnostics, digital care, and therapeutics, and a local investor base that knows how to fund them.
The firms here back more than medtech. Healthcare services, life sciences, biotech, and healthtech appear on most profiles, and several also invest in fintech and SaaS. For the wider set of venture capital firms in Sweden, or for medtech venture capital firms outside Sweden, see the related lists.
Who backs medtech startups in Sweden
HealthCap
HealthCap is a Stockholm venture capital firm founded in 1996 that specializes in life sciences, with a focus on therapies for rare diseases, cancers, and genetic disorders. It invests from seed through late stage with checks of $10 million to $50 million, states that it has funded over 130 companies with 48 IPOs, and counts Spruce Biosciences and Aprea Therapeutics in its portfolio. It suits founders targeting a high unmet medical need who want a team with backgrounds in medicine and biochemistry.
Industrifonden
Industrifonden is a Swedish venture capital fund founded in 1979 that backs deep tech and life sciences, naming medtech, healthtech, biotech, and synthetic biology among its interests. It covers pre-seed to late stage with checks of $10 million to $50 million, manages 5 billion SEK in assets, and holds Pixelgen, AnaCardio, and Asgard Therapeutics. Science-heavy teams looking for a long-term owner across several rounds should start here.
Eir Ventures
Eir Ventures is a Stockholm life science venture capital firm founded in 2020, run by a team of PhDs and MDs with an active ownership model built on company creation and board seats. It invests from seed to late stage with checks of $10 million to $50 million, and its portfolio includes Moleculent, ArgusEye, and Cinclus Pharma. Founders who want a hands-on board partner, or researchers still forming a company around a discovery, will find a close fit.
Almi Invest
Almi Invest is a Stockholm venture capital firm and part of Almi Företagspartner AB, investing across Sweden in technology, life sciences, deep tech, and sustainability. It writes checks under $1 million at pre-seed, seed, and early growth stages, often alongside other investors, and has backed Navari Surgical and Aligned Bio. It is a natural first call for a medtech founder raising a first institutional round.
Norrsken VC
Norrsken VC is an early-stage, impact-driven venture capital firm founded in 2016 that grew out of the Norrsken Foundation and invests in healthcare, energy, and industry. It joins pre-seed, seed, and Series A rounds with checks of $1 million to $5 million, and its health holdings include Biorce and Oviva. Teams whose product addresses a large health or societal problem match its mandate best.
Creandum
Creandum is a generalist venture capital firm founded in 2003 in Sweden, with hubs abroad including San Francisco, backing technology companies from pre-seed to Series A. It writes checks of $10 million to $50 million, its latest fund is Creandum VIII, launched in 2026 at $750 million, and its portfolio includes Kry next to Spotify and Klarna. Software-led medtech and digital health teams with international ambitions are its most likely fit.
How to shortlist medtech investors from this list
- Match your stage first. Almi Invest and Norrsken VC focus on pre-seed to Series A, while HealthCap, Eir Ventures, and Industrifonden also follow companies into later rounds.
- Separate therapeutics from devices and software. HealthCap and Eir Ventures lean toward drug development, while Creandum and Norrsken VC lean toward digital care and tech-enabled models.
- Use the check size filter above the list. Ask for an amount that sits inside a firm's usual range, since most firms here write larger tickets and only a few write checks under $1 million.
- Check the firm type. A few firms on the full list also invest as private equity, two are family offices, and one is a corporate VC. Revenue-stage companies seeking growth or buyout capital can compare medtech private equity firms in Sweden.
- Read portfolios for overlap. A firm already backing a direct competitor is unlikely to invest in you.
Private Equity List gives you a profile for every firm on this page, with partner contacts and filters by sector, stage, and check size, so you can build a short, relevant outreach list before your next round.